Table 1.
Demographic and clinical data.
| All n = 199 |
Group 1 n = 113 (57%) |
Group 2 n = 86 (43%) |
p Value Mismatch vs. Non-Mismatch |
||
|---|---|---|---|---|---|
| Sex (n, female) | 145 (73%) | 80 (71%) | 65 (76%) | n.s. | |
| Age at diagnosis (years) | 28.0 | 27.9 | 28.1 | n.s. | |
| Age at current relapse (years) | 32.9 | 31.2 | 35.2 | 0.013 | |
| Diagnosis of MS with current relapse | 41% | 55% | 22% | <0.001 | |
| No of relapses before </= 2 | 60.8% | 75.4% | 43.1% | <0.001 | |
| Disease duration (months) | 71.3 | 45.6 | 105.1 | <0.001 | |
| EDSS in current relapse < 3.0 | 57.8% | 58.3% | 57.0% | n.s. | |
| Functional system concerned | |||||
| brainstem/ cranial nerves |
39.2% | 43.4% | 33.7% | n.s. | |
| motoric dysfunction | 31.7% | 25.7% | 39.5% | 0.038 | |
| sensory | 54.8% | 51.3% | 59.3% | n.s. | |
| coordination/ataxia | 12.6% | 12.4% | 12.8% | n.s. | |
| bowel/bladder | 4.0% | 3.5% | 4.7% | n.s. | |
| others | 1.5% | 1.8% | 1.2% | n.s. | |
| Treatment with MPS | 95% | 98% | 91% | n.s. | |
| 3 g | 34.7% | 24.8% | 47.7% | <0.001 | |
| 5 g | 40.2% | 52.2% | 24.4% | <0.001 | |
| 15 g | 6.5% | 8.0% | 4.7% | n.s. | |
| other doses | 18.6% | 15.0% | 23.2% | n.s. | |
| DMT | 52.5% | 45.1% | 58.2% | n.s. | |
| MRI with 3.0 T | 43.2% | 43.4% | 43.0% | n.s. | |
Abbreviations: n.s. = not significant, MS = multiple sclerosis, EDSS = Expanded Disability Status Scale, MPS = methyl prednisolone, DMT = disease modifying therapy, MRI = magnetic resonance imaging.